动物造模 z-bio 2021-07-15 397

　　Objective: To study the effect of TGF-β1 gene therapy on the rat model of postpartum stress urinary incontinence, and to explore an ideal new non-surgical treatment method.

　　Method: Model 240 SD female rats using vasovaginal dilatation, randomly selected 148 from 185 successful models, divided into 5 groups, TGF-β1 gene therapy, ammonia antagonist treatment, and electrical stimulation. Treatment, empty plasmid vector injection and no treatment. In addition, 20 unestablished rat models were selected as blank controls. Sneeze tests, urodynamic tests, and pelvic pubic-coccygeal strength were performed 1, 21, 42 and 63 days after treatment. /ELISA method to detect muscle weight ratio, TGF-1, immunohistochemical detection of TGF-β1,

　　Results: Regardless of the maximum bladder volume, leakage point pressure, contractile force/muscle weight ratio, the therapeutic effect of the TGF-β1 gene therapy group increased 21 days after treatment, but there were differences in electrical therapy. None. Significant in the stimulation group (P→0.05).

　　Conclusion: TGF-β1 gene therapy has the potential to become a new type of non-surgical treatment, which may have a positive effect on rats with postpartum stress urinary incontinence.